Viera Lukacova

Viera Lukacova

Auto-generated profile, based on publicly available information

Viera Lukacova

Simulations Plus, Inc., Durham, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2025 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
Daniela Amaral SilvaDaniela Amaral Silva
Daniela Amaral Silva
MMMaxime Le Merdy
Maxime Le Merdy
JMJames Mullin
James Mullin
NMNilesh Malavia
Nilesh Malavia
KAKhondoker Alam
Khondoker Alam
VLViera Lukacova
Viera Lukacova
The tissue response to long-acting injectables (LAIs) suspension injection may impact the product in vivo performance. One such response is the formation of an inflammatory cell layer (ICL) resulting in an envelope around the injected particles. This study aims to use a mechanistic model to describe the clinical in vivo exposure and performance of an intramuscular LAI suspension and evaluate impact of ICL physiological response at the injection site in humans. Aripiprazole lauroxil (AR-L) was used as the model drug. A baseline pharmacokinetics model was built and validated for aripiprazole. The impact of inflammation on the LAI in vivo performance was assessed by including an ICL model. The developed pharmacokinetic model adequately described the observed plasma profiles of AR following intravenous and oral administration in humans. The initial intramuscular predictions assumed that the absorption rate is dependent on the dissolution and partitioning of AR-L into the systemic circulation from the intramuscular (IM) depot. The simulation resulted in a shape mismatch between the simulated and observed data and an earlier predicted T max. The inclusion of an ICL in the model resulted in adequate predictions (fold errors less than 25%) of the exposure and shape of the plasma concentration–time profiles. Utilizing a time-dependent change in ICL thickness resulted in reasonable predictions of AR pharmacokinetic profiles following IM administration of multiple strengths of the AR-L suspension. This shows the utility of physiologically based pharmacokinetic (PBPK) model in mechanistically describing the in vivo performance of LAIs. Graphical Abstract